Organon (OGN) Intangibles (2020 - 2026)
Organon (OGN) recorded quarterly Intangibles of $1.1 billion in Q1 2026, down 2.74% quarter-over-quarter from $1.1 billion in Q4 2025, and up 2054.9% on a YoY basis from $51.0 million in Q1 2025.
Organon (OGN) Intangibles (2020 - 2026) Analysis & Trends
Organon's Intangibles history runs 7 years deep, the most recent figure standing at $1.1 billion for Q1 2026.
- In Q1 2026, Intangibles rose 2054.9% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (up 2054.9% YoY), while the FY2025 annual figure was $1.1 billion, down 20.08% from the prior year.
- Intangibles was $1.1 billion for Q1 2026 at Organon, down from $1.1 billion in the prior quarter.
- In the past five years, Intangibles ranged from a high of $24.5 billion in Q4 2023 to a low of $30.0 million in Q3 2025.
- Historically, Intangibles has averaged $2.1 billion across 5 years, with a median of $649.0 million in 2022.
- The sharpest annual moves came in 2023 and 2024: Intangibles soared 3678.27% in 2023, then plunged 94.23% in 2024.
- A 5-year view of Intangibles shows it stood at $649.0 million in 2022, then jumped by 3678.27% to $24.5 billion in 2023, then slumped by 94.23% to $1.4 billion in 2024, then declined by 20.08% to $1.1 billion in 2025, then declined by 2.74% to $1.1 billion in 2026.
- The last three Intangibles figures came in at $1.1 billion (Q1 2026), $1.1 billion (Q4 2025), and $30.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn | 24.45 Bn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn | 7.37 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn | 49.06 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn | 50.87 Bn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn | 25.75 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn | 21.38 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 16.38 Bn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn | 52.56 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn | 18.24 Bn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn | 1.10 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.10 Bn |
| Dec 31, 2025 | 1.13 Bn |
| Sep 30, 2025 | 30.00 Mn |
| Jun 30, 2025 | 1.36 Bn |
| Mar 31, 2025 | 51.00 Mn |
| Dec 31, 2024 | 1.41 Bn |
| Sep 30, 2024 | 113.00 Mn |
| Jun 30, 2024 | 684.00 Mn |
| Mar 31, 2024 | 220.00 Mn |
| Dec 31, 2023 | 24.52 Bn |
| Sep 30, 2023 | 561.00 Mn |
| Jun 30, 2023 | 592.00 Mn |
| Mar 31, 2023 | 621.00 Mn |
| Dec 31, 2022 | 649.00 Mn |
| Sep 30, 2022 | 670.00 Mn |
| Jun 30, 2022 | 638.00 Mn |
| Mar 31, 2022 | 665.00 Mn |
| Dec 31, 2021 | 651.00 Mn |
| Sep 30, 2021 | 683.00 Mn |
| Jun 30, 2021 | 711.00 Mn |